Real-Time News FIRE FAST SIP Calculators

Easy-to-understand Financial Insights
that build Wealth.

Explore Dzambhala NodeX

BIOCON

NSE: BIOCON | BSE: 532523

Latest on BIOCON

Biocon Gets Tentative FDA Approval for Sitagliptin Tablets to Boost Diabetes Treatment Portfolio August 26, 2025 | 9:04 p.m. IST
Biocon Joins 'Saksham Niveshak' Campaign to Assist Shareholders in Claiming Unpaid Dividends August 20, 2025 | 7:24 p.m. IST
Biocon Reports Q1 FY26 Revenue of ₹3,942 Cr, Marks First Equity Raise Since IPO with ₹4,500 Cr QIP August 14, 2025 | 7:56 p.m. IST
Biocon Declares 10% Final Dividend and Approves Key Resolutions at 47th AGM August 11, 2025 | 11:50 p.m. IST
Biocon Re-appoints Prof. Ravi Mazumdar and Naina Lal Kidwai as Directors During 47th AGM August 8, 2025 | 7:11 p.m. IST
Biocon Reports 5% Revenue Growth to ₹16,469.9 Cr in 47th AGM, Highlights New Product Launches and QIP of ₹4,500 Cr August 8, 2025 | 7:10 p.m. IST
Biocon Declares Final Dividend of ₹0.50 Per Share During 47th AGM August 8, 2025 | 6:47 p.m. IST
Biocon Reports ₹4,022 Cr Revenue for Q1 FY26, Raises ₹4,500 Cr Through QIP and Secures Key FDA Approvals August 8, 2025 | 8:46 a.m. IST
Biocon Submits Q1 FY 2025-26 Monitoring Agency Report, Confirms No Deviations in QIP Fund Utilisation August 7, 2025 | 9:25 p.m. IST
Biocon Reports Q1FY26 Revenue of ₹3,942 Cr, Net Profit Soars 342% to ₹31 Cr August 7, 2025 | 8:30 p.m. IST
Biocon Foundation Collaborates with IISc to Combat Oral Cancer Through New Initiatives July 28, 2025 | 2:45 p.m. IST
Biocon Biologics Appoints Deepali Naair as Global Head of Brand & Corporate Communications July 23, 2025 | 12:39 p.m. IST
Biocon Biologics Launches Nepexto® Biosimilar in Australia to Expand Immunology Portfolio July 23, 2025 | 8:52 a.m. IST
Biocon Seeks Shareholder Approval to Boost Authorised Share Capital to ₹700 Cr and Raise ₹4,500 Cr Through Equity Issuance May 5, 2025 | 3:33 p.m. IST
Biocon Biologics Secures Access for Yesintek™ in US, Now Covered for Over 100 Million Lives May 5, 2025 | 8:40 a.m. IST
Biocon Biologics Gets Positive CHMP Recommendations for Denosumab Biosimilars in Europe April 26, 2025 | 11:32 a.m. IST
Biocon Plans To Raise ₹4,500 Cr Through Fund Issuance, Seeks Shareholder Approval April 23, 2025 | 8:41 p.m. IST
Biocon Issues ₹600 Cr Commercial Papers with 7.75% Interest Rate, Maturity in September 2025 April 22, 2025 | 8:20 p.m. IST
Biocon To Seek Shareholder Approval For Fundraising Through Equity Shares In Upcoming Board Meeting April 20, 2025 | 2:18 p.m. IST
Biocon Secures 'IND A1+' Credit Rating for ₹1200 Cr Commercial Paper Programme April 15, 2025 | 7:59 p.m. IST
Biocon Biologics Secures U.S. Market Entry for Yesafili™ Biosimilar After Settling Patent Litigation with Regeneron April 15, 2025 | 8:21 a.m. IST
Biocon Secures US FDA Approval for Everolimus Tablets, Expanding Its Complex Drug Portfolio April 10, 2025 | 10:12 p.m. IST
Biocon Secures U.S. FDA Approval for Jobevne™, Expanding Oncology Portfolio With Seventh Biosimilar April 10, 2025 | 5:10 p.m. IST
Biocon Board Approves Issuance of ₹600 Cr in Commercial Papers for Fundraising April 4, 2025 | 9:01 p.m. IST
Biocon To Approve Q4 Financial Results and Consider Dividend on May 8, 2025; Earnings Call Scheduled for May 9 April 2, 2025 | 5:27 p.m. IST
Biocon To Hold Board Meeting on May 8 To Approve FY 2024-25 Results and Consider Dividend April 2, 2025 | 5:16 p.m. IST
Biocon Secures 99.99% Shareholder Approval for Related Party Transactions with Subsidiaries April 2, 2025 | 3:47 p.m. IST
Biocon Secures Shareholder Approval with 99.99% Vote for Related Party Transactions April 2, 2025 | 3:47 p.m. IST
Biocon CEO Peter Bains Resigns to Lead Syngene International as MD & CEO April 1, 2025 | 10:58 p.m. IST
Biocon Secures FDA Approval for Norepinephrine Bitartrate Injection, Boosting Complex Drug Portfolio March 24, 2025 | 8:59 a.m. IST
Biocon Reports Successful Phase 3 Study Results for Yesintek™ Biosimilar in Chronic Plaque Psoriasis Treatment March 7, 2025 | 6:50 p.m. IST
Biocon Partners with Civica to Supply Insulin Aspart, Aiming to Improve Affordability for 38.4 Million Diabetics in the US March 6, 2025 | 5:34 p.m. IST
Biocon Pharma Secures FDA Final Approvals for Lenalidomide and Dasatinib, Gains Tentative Approval for Rivaroxaban March 4, 2025 | 6:31 p.m. IST
Biocon Academy Celebrates 9th Graduation Day with 165 Students Completing Biotech Programmes March 4, 2025 | 11:36 a.m. IST
Biocon Foundation Celebrates 20 Years of Impact, Benefiting 2.8 Million Lives Across India February 28, 2025 | 6:06 p.m. IST
Biocon Launches GLP-1 Peptide Liraglutide in the UK for Diabetes and Obesity Management February 28, 2025 | 8:56 a.m. IST
Biocon Seeks Approval for ₹1,000 Cr Related Party Transaction to Streamline Operations February 27, 2025 | 6:44 p.m. IST
Biocon Hit With ₹89.23 Lac Penalty Over GST Compliance Violations, Plans To Appeal February 25, 2025 | 3:54 p.m. IST
Biocon Biologics Launches Yesintek™ Biosimilar in US for Chronic Autoimmune Diseases February 24, 2025 | 5:07 p.m. IST
Biocon Secures European Marketing Authorisation for Ustekinumab Biosimilar YESINTEK® February 18, 2025 | 8:42 a.m. IST
Biocon Foundation Launches 'Pillars of Bengaluru' Art Initiative to Celebrate City Champions February 11, 2025 | 3:13 p.m. IST
Biocon Submits Corporate Presentation Highlighting 14% Revenue Growth and Focus on Biosimilars February 3, 2025 | 1:59 p.m. IST
Biocon Reports Q3 FY2024 Revenue of ₹38,214 Lac and Net Profit of ₹251 Lac February 1, 2025 | 2:17 p.m. IST
Biocon Acquires 1.98 Cr Shares in Biocon Biologics for ₹555 Cr, Boosting Stake to 90.2% January 31, 2025 | 7:45 p.m. IST
Biocon Reports Q3 FY2024 Net Profit Surge to ₹5,840 Million Amid Strategic Equity Moves January 31, 2025 | 4:31 p.m. IST
Biocon Reports Q3 FY25 Revenue of ₹3,856 Cr, Net Profit Plummets 96% to ₹25 Cr January 31, 2025 | 8:45 a.m. IST
Biocon Reports Q3 FY2024-25 Results With Net Profit Jumping to ₹5,840 Million and Exceptional Gains of ₹6,075 Million January 30, 2025 | 10:01 p.m. IST
Biocon Acquires ₹555 Cr Stake in Biocon Biologics, Boosting Ownership to 90.2% January 30, 2025 | 8:55 p.m. IST
Biocon Reports Q3 FY2024-25 Net Profit Surge to ₹5,840 Million Despite Income Dip January 30, 2025 | 8:54 p.m. IST
Biocon's Company Secretary Mayank Verma Resigns to Pursue New Opportunities January 30, 2025 | 8:54 p.m. IST
Biocon Reports Q3 FY2024 Net Profit Surge to ₹5,840 Million Despite Decline in Total Income January 30, 2025 | 8:32 p.m. IST
Biocon Reports Q3FY25 Revenue of ₹3,856 Cr, Net Profit Falls to ₹25 Cr Amid Mixed Performance January 30, 2025 | 8:30 p.m. IST
Biocon Issues ₹570 Cr in Commercial Papers with 90-Day Tenure and 8.75% Interest Rate January 29, 2025 | 8:57 p.m. IST
Biocon Schedules Investor Meetings in London and Edinburgh from February 3-5, 2025 January 28, 2025 | 4:37 p.m. IST
Biocon To Hold Board Meeting on January 27 to Approve Fundraising Through Commercial Papers January 22, 2025 | 11:03 p.m. IST
Biocon's Credit Ratings Updated: Non-Convertible Debenture Rated IND AA+ and New Commercial Papers Rated IND A1+ January 22, 2025 | 10:51 p.m. IST